xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

293

ICAR SINONASAL TUMORS

TABLE XXV.6 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

Yuanet al. 1686

1. Combination treatment improved the CR rate of primary NPC and metastatic lymph nodes, also 1-year DMFS rate 2. No significant difference in 2 and 3-year DMFS rates

1. CR rate for primary

2015 2

Meta-analysis 821 patients in 12 cohorts Conventional treatment (RT or CRT) vs

tumor and metastatic lymph nodes

2. DMFS

combination treatment (adding anti-EGFR

monoclonal antibodies to conventional treatment)

Chenet al. 1680 Li et al. 1681

2011,

updated 2019 2

RCT

230 patients with stage II (T1-2N1M0 or T2N0M0) NPC (Chinese 1992

1. OS 2. PFS, DMFS andLRFS

1. CRT group had significantly improved outcome for stage II NPC compared with RT group in terms of 5-year OS, PFS, and DMFS 2. CRT group significantly improved 10-year OS, PFS, DSS, and DMFS compared with RT group 3. No significant difference in 5 and 10-year LRFS rate for CRT versus RT groups 4. Survival benefit of chemotherapy mainly reflected in T2N1 population after reclassifying the patients in AJCC 7th edition, but did not show superiority in T1N1 and T2N0 patients significantly more acute grade 3–4 toxic effects than in RT group, and the rate of late toxic effects did not increase statistically significantly in both 5 and 10 years 1. No difference in DFS between CTX/NTZ group and cisplatin group 2. No difference in 3-year LRFS, DMFS, and OS 3. Significantly increased hematologic toxicities and gastrointestinal reactions were observed in the cisplatin group 5. CRT arm experienced

staging system) of WHO type II/III NPC

RT versus CRT

Youet al. 1685

1. 3-year DFS 2. 3-year OS,

1837 patients with

2017 3*

Retrospective

stage II–IVb NPC, 3:1 matched cohort for cisplatin + IMRT versus (CTX)/NTZ + IMRT

case–control study

PFS, LRFS, andDMFS

4. Increased rate of CTX

related-skin reaction and mucositis was observed in the CTXgroup Abbreviations: CR, complete response; CTX, cetuximab; DMFS, distant metastasis-free survival; LRFS, locoregional failure/recurrence-free survival; NTZ, nimotuzumab; NPC, nasopharyngeal carcinoma; OS, overall survival; PFS, progression-free survival; RRFS, regional recurrence-free survival. *Upgraded given large sample size.